Pluri Inc. (PLUR) - Total Liabilities
Based on the latest financial reports, Pluri Inc. (PLUR) has total liabilities worth $39.81 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Pluri Inc. (PLUR) cash flow conversion to assess how effectively this company generates cash.
Pluri Inc. - Total Liabilities Trend (2002–2025)
This chart illustrates how Pluri Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Pluri Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Pluri Inc. Competitors by Total Liabilities
The table below lists competitors of Pluri Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Above Food Ingredients Inc. Common Stock
NASDAQ:ABVE
|
USA | $227.56 Million |
|
Verena Multi Finance Tbk
JK:VRNA
|
Indonesia | Rp2.32 Trillion |
|
Investors House
HE:INVEST
|
Finland | €20.00 Million |
|
HPP Holdings Bhd
KLSE:0228
|
Malaysia | RM31.62 Million |
|
JAS Asset PCL
BK:J
|
Thailand | ฿3.18 Billion |
|
Auris Minerals Ltd
AU:AUR
|
Australia | AU$253.26K |
|
Bellway PLC
LSE:BWY
|
UK | GBX1.64 Billion |
|
CL Educate Limited
NSE:CLEDUCATE
|
India | Rs7.17 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Pluri Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PLUR market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pluri Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pluri Inc. (2002–2025)
The table below shows the annual total liabilities of Pluri Inc. from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $39.55 Million | +15.94% |
| 2024-06-30 | $34.11 Million | -3.90% |
| 2023-06-30 | $35.50 Million | -1.06% |
| 2022-06-30 | $35.88 Million | -1.40% |
| 2021-06-30 | $36.39 Million | +285.82% |
| 2020-06-30 | $9.43 Million | -0.61% |
| 2019-06-30 | $9.49 Million | -9.22% |
| 2018-06-30 | $10.45 Million | +43.53% |
| 2017-06-30 | $7.28 Million | -6.45% |
| 2016-06-30 | $7.79 Million | -22.24% |
| 2015-06-30 | $10.01 Million | -15.87% |
| 2014-06-30 | $11.90 Million | +9.68% |
| 2013-06-30 | $10.85 Million | +12.11% |
| 2012-06-30 | $9.68 Million | +273.09% |
| 2011-06-30 | $2.59 Million | +58.07% |
| 2010-06-30 | $1.64 Million | +53.51% |
| 2009-06-30 | $1.07 Million | -14.82% |
| 2008-06-30 | $1.25 Million | +51.25% |
| 2007-06-30 | $829.74K | -79.61% |
| 2006-06-30 | $4.07 Million | +398.09% |
| 2005-06-30 | $816.91K | -19.93% |
| 2004-06-30 | $1.02 Million | +102.35% |
| 2003-06-30 | $504.18K | +448.38% |
| 2002-06-30 | $91.94K | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more